0.4316
price up icon46.31%   0.1366
after-market After Hours: .38 -0.0516 -11.96%
loading
Genprex Inc stock is traded at $0.4316, with a volume of 62.55M. It is up +46.31% in the last 24 hours and up +24.02% over the past month.
See More
Previous Close:
$0.295
Open:
$0.32
24h Volume:
62.55M
Relative Volume:
18.50
Market Cap:
$3.67M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0369
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+26.20%
1M Performance:
+24.02%
6M Performance:
+30.79%
1Y Performance:
-86.12%
1-Day Range:
Value
$0.2853
$0.4366
1-Week Range:
Value
$0.22
$0.4366
52-Week Range:
Value
$0.22
$4.0899

Genprex Inc Stock (GNPX) Company Profile

Name
Name
Genprex Inc
Name
Phone
512-537-7997
Name
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Name
Employee
0
Name
Twitter
@genprex
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
GNPX's Discussions on Twitter

Compare GNPX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GNPX
Genprex Inc
0.4316 3.67M 0 -22.71M -18.24M -11.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Genprex Inc Stock (GNPX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-26-21 Initiated National Securities Buy
Apr-29-19 Initiated Noble Capital Markets Outperform

Genprex Inc Stock (GNPX) Latest News

pulisher
Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Apr 02, 2025
pulisher
Apr 01, 2025

Genprex Delays Yearly Report Filing - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Genprex Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Genprex, Inc. SEC 10-K Report - TradingView

Apr 01, 2025
pulisher
Mar 31, 2025

Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 28, 2025

Genprex stock plunges to 52-week low of $0.27 - Investing.com

Mar 28, 2025
pulisher
Mar 26, 2025

Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Genprex reports progress in lung cancer gene therapy - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire

Mar 26, 2025
pulisher
Mar 25, 2025

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Quantisnow

Mar 25, 2025
pulisher
Mar 25, 2025

Game-Changing Gene Therapy Could End Daily Insulin Injections for Diabetes Patients - Stock Titan

Mar 25, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025
pulisher
Mar 14, 2025

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® De - GuruFocus.com

Mar 14, 2025
pulisher
Mar 13, 2025

Genprex Inc (GNPX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register

Mar 13, 2025
pulisher
Mar 04, 2025

Genprex to Participate at BIO Europe Spring 2025 - StreetInsider.com

Mar 04, 2025
pulisher
Mar 04, 2025

Can Genprex's Presence at BIO Europe Spring Attract New Partnership Opportunities? - Stock Titan

Mar 04, 2025
pulisher
Feb 27, 2025

Genprex to Present at the 2020 LD Micro Virtual Conference - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 20, 2025

Genprex Strengthens Diabetes Focus with New License - TipRanks

Feb 20, 2025
pulisher
Feb 19, 2025

Genprex explores non-viral gene therapy for diabetes By Investing.com - Investing.com Nigeria

Feb 19, 2025
pulisher
Feb 19, 2025

Genprex Advances Diabetes Program With Addition Of Research Focused On Non-Viral Delivery System - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Genprex explores non-viral gene therapy for diabetes - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Delivery System Transform Diabetes Gene Therapy? Genprex's Latest Breakthrough - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

Genprex advances diabetes gene therapy with new license By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex Provides Update On Diabetes Gene Therapy Program -February 18, 2025 at 10:03 am EST - Marketscreener.com

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex announces advancement of its diabetes gene therapy program - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex advances diabetes gene therapy with new license - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Genprex Provides Update on Diabetes Gene Therapy Program - Nasdaq

Feb 18, 2025
pulisher
Feb 14, 2025

Genprex faces Nasdaq delisting over stock price, equity issues - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - BioSpace

Feb 14, 2025
pulisher
Feb 13, 2025

Genprex's New Study Highlights NPRL2 Gene Therapy's Antitumor Activity In Lung Cancer - Nasdaq

Feb 13, 2025
pulisher
Feb 13, 2025

Understanding GNPX’s financial ratios: A beginner’s guide - US Post News

Feb 13, 2025
pulisher
Feb 13, 2025

Major Cancer Treatment Breakthrough: New Gene Therapy Defeats Drug-Resistant Lung Cancer - Stock Titan

Feb 13, 2025
pulisher
Feb 12, 2025

Genprex faces Nasdaq delisting over stock price, equity issues By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 06, 2025

Contrasting Genprex (NASDAQ:GNPX) & Avadel Pharmaceuticals (NASDAQ:AVDL) - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle

Feb 05, 2025
pulisher
Jan 24, 2025

Genprex Inc (NASDAQ: GNPX): An Enticing Stock To Watch - Stocks Register

Jan 24, 2025
pulisher
Jan 24, 2025

Genprex doses first subject in expansion part of lung cancer gene therapy trial - Clinical Trials Arena

Jan 24, 2025
pulisher
Jan 23, 2025

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire

Jan 23, 2025
pulisher
Jan 15, 2025

Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance

Jan 14, 2025
pulisher
Jan 06, 2025

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace

Jan 06, 2025
pulisher
Dec 20, 2024

SEC Form 424B5 filed by Genprex Inc. - Quantisnow

Dec 20, 2024

Genprex Inc Stock (GNPX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):